Role of Nonsteroidal Topical Therapies in AD Management
Experts in the management of atopic dermatitis review the safety and efficacy of topical calcineurin inhibitors and topical PDE4 inhibitors.
Target Dose in HF Therapies for Reduced Ejection Fraction
Contraindications for clinicians to keep in mind when administering sacubitril/valsartan therapy, and an examination of target dose for therapies in heart failure with reduced ejection fraction.
Considering ARNIs as De Novo Therapy in Heart Failure
Considerations for initiating sacubitril/valsartan as de novo therapy in patients naïve to angiotensin-converting enzyme inhibitors or angiotensin receptor blocker therapies as per the 2021 update of the expert consensus decision pathway document.
Understanding When to Start LAIs in Schizophrenia
Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, review how early long-acting injectables should be started in patients with schizophrenia.
Transitioning from Oral to LAIs to Manage Schizophrenia
Henry Nasrallah, MD, and Rahn Bailey, MD, DFAPA, discuss how to switch a patient from oral to a long-acting injectable antipsychotic from their own experience.
Are Recommendations Infringing Upon Practice Autonomy?
Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy.
December 2020 CDC Health Alert Highlights and Implementation
Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.
Management of AD: Nonpharmacological Approaches
Peter Lio, MD, and Elizabeth Swanson, MD, provide insight on using nonpharmacological therapies and state-of-the-art skin care treatments for patients with atopic dermatitis.
Patient Factors for Treatment of Atopic Dermatitis
Patient factors considered when prescribing treatment options for the management of atopic dermatitis.
Using Sacubitril/Valsartan in Heart Failure Treatment
A discussion on the safety and efficacy of angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, for the treatment of heart failure.
Evolution of Heart Failure Treatments
Experts in cardiology provide a brief history on treatments used for heart failure including ACE (angiotensin converting enzyme) inhibitors and beta blockers.
LAIs in Schizophrenia: Advantages and Techniques for Patient Acceptance
Joe Avelino, RN, BSN, MHSA, CPHQ, reviews the benefits of using long-acting injectables (LAIs) and Henry Nasrallah, MD, reviews his techniques for getting patients to accept LAIs and continue with them.
Patient Factors Associated with Schizophrenia
Henry Nasrallah, MD, discusses patient factors that lead to long-acting injectable treatment in patients with schizophrenia.
Barriers to Naloxone Prescribing, Dispensing, and Utilization
Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.
Normalizing the Conversation about Naloxone with the Public
Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.
New Models of Collaborative Care for Atopic Dermatitis
Reviewing the importance of newer models of collaboration between specialty and primary care for atopic dermatitis and educating patients and caregivers for disease management.
Optimizing Multidisciplinary Care for Atopic Dermatitis
Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss the importance of an integrative approach to care for the management of atopic dermatitis.